Pursuant to the sublicensing agreement, Cytocom will assume the following approximate obligations of the Company: $1,051,000 in accrued liabilities and accounts payable, $3,038,000 in notes and loans payable, and $1,111,000 in obligations owed to former Immune employees.
What is the company's forward looking transition strategy? What do they have besides a 15% stake in Cyctocom? If it is true that it was too expensive and not profitable enough to proceed with LDN in emerging markets then great we got rid of 5 million dollars in financial obligations. What is the plan going forward? Do they have one?
Market Data 
Markets 
